Fate Therapeutics
FATE
239 hedge funds and large institutions have $2.41B invested in Fate Therapeutics in 2022 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 83 increasing their positions, 81 reducing their positions, and 26 closing their positions.
85% more call options, than puts
Call options by funds: $2.87M | Put options by funds: $1.55M
27% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 26
3% more funds holding
Funds holding: 233 → 239 (+6)
2% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 81
2.2% less ownership
Funds ownership: 113.36% → 111.16% (-2.2%)
10% less capital invested
Capital invested by funds: $2.7B → $2.41B (-$282M)
44% less funds holding in top 10
Funds holding in top 10: 9 → 5 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$15.5M |
| 2 |
BlackRock
New York
|
+$14.5M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
+$9.57M |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$7.1M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$6.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$53.2M |
| 2 |
State Street
Boston,
Massachusetts
|
-$25.6M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$20.4M |
| 4 |
EP
Eversept Partners
New York
|
-$16.9M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$11.6M |
FATE Hedge Fund Activity: Q3 2022 in Review
239 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q3 2022, worth a combined $2.41B — down 10% from $2.7B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new FATE positions and 26 closed out — a net gain of 7 holders — while 83 added to existing stakes and 81 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $15.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $53.2M.
- 239 institutional investors held Fate Therapeutics (FATE) as of Q3 2022, up from 233 in Q2 2022.
- Funds reported $2.41B of Fate Therapeutics stock for Q3 2022, down 10% quarter-over-quarter.
- 33 funds opened new Fate Therapeutics positions in Q3 2022 and 26 closed out, a net change of +7 holders.
- The largest Fate Therapeutics buyer in Q3 2022 was Renaissance Technologies, an estimated $15.5M added.
- The largest Fate Therapeutics seller in Q3 2022 was T. Rowe Price Associates, an estimated $53.2M sold.
Based on aggregated 13F filings for Q3 2022.